Barbados’ regulated medicinal cannabis sector is poised for significant expansion in 2026, with two new facilities advancing toward operational status, according to official statements from the island’s regulatory authority. Shanika Roberts-Odle, Acting CEO of the Barbados Medicinal Cannabis Licensing Authority (BMCLA), confirmed the developments during a public open day event at Island Naturals Medical Centre in Sheraton Mall, marking the organization’s fifth anniversary.
The forthcoming facilities will operate within the pharmacy and therapeutic categories, providing supervised medical access to cannabis products under Barbados’ strict regulatory framework. This expansion follows the successful launch of two businesses in 2025, demonstrating what Roberts-Odle characterized as ‘tangible progress’ in an industry that requires long-term development strategies.
Currently, the BMCLA has issued approximately 12 licenses spanning the entire value chain, including cultivation, manufacturing, retail, transportation, security, and research—with one license held by The University of the West Indies. While some licensees are already operational, others continue navigating substantial business, financial, and logistical challenges.
Roberts-Odle identified international banking restrictions as the most significant obstacle facing the industry, directly linking these constraints to the continued federal prohibition of cannabis in the United States. ‘We do not exist in isolation,’ she emphasized. ‘Because the U.S. maintains federal prohibition, our local banks—which all maintain U.S. correspondent relationships—are reluctant to engage with cannabis businesses.’
Despite these hurdles, the acting CEO urged collaboration and persistence, noting the industry has demonstrated remarkable resilience. She advised prospective entrepreneurs to ‘work together as a group of individuals’ and emphasized the BMCLA’s willingness to facilitate problem-solving dialogues.
The open day event formed part of a broader public education initiative addressing decades of stigma associated with cannabis use. Roberts-Odle stressed that changing public perceptions requires sustained exposure and open discussion, contrasting regulated medical facilities with illicit market operations.
At the Sheraton Mall facility, patients can access diverse medicinal products including locally cultivated cannabis flowers, creams, oils, tinctures, and vaporizer products—some imported from international sources. This differs from the Island Therapeutics facility in Worthing, which focuses primarily on Barbados-grown flowers and pharmacist-compounded products.
Roberts-Odle clarified that the authority does not interfere with doctor-patient relationships or restrict conditions eligible for cannabis treatment, trusting Barbadian medical professionals to make appropriate decisions. Common applications include cancer-related pain and nausea, multiple sclerosis symptoms, arthritis, endometrial pain, and sleep disorders—though she emphasized that ‘cannabis is not snake oil’ but rather ‘another tool in the toolbox’ that may not be suitable for everyone.
Regarding regulatory compliance, Roberts-Odle explained that legal access requires a prescription from registered medical practitioners, either private doctors or on-site physicians at approved facilities. She specifically addressed misconceptions about membership cards, noting that prescription labels—not cards—provide legal protection. While some patients have been stopped by authorities, she reported that issues were promptly resolved upon presentation of proper documentation.
The regulatory framework explicitly prohibits smoking medicinal cannabis, permitting only vaping, oils, creams, and tinctures as approved consumption methods.